Company news
Amarantus Bioscience Holdings, Inc. news in 2016
Amarantus Bioscience Holdings, Inc.'s news releases, calls and decks from 2016, newest first.
Amarantus Announces Publication of Human Clinical Data for Engineered Skin Substitute in the Treatment of Life-Threatening Pediatric Severe Burns
August 8, 2016
Avant Diagnostics Presented Data on TheraLink® Pancreatic Cancer Assay at the International Symposium on Pancreas Cancer 2016
June 14, 2016
Amarantus Announces cGMP Manufacturing Readiness for Its Engineered Skin Substitute (ESS) Program at Lonza Walkersville
June 7, 2016
Amarantus Completes Sale of Diagnostics Division, Announces Fiscal Year 2015 and First Quarter 2016 Financial Results
June 3, 2016
OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
May 31, 2016
Amarantus Announces Upcoming Investor Presentations
May 27, 2016
Avant Diagnostics Simultaneously Completes Acquisitions of Amarantus Diagnostics and Theranostics Health
May 12, 2016
Retired American Burn Association President Dr. David Ahrenholz to Present on Engineered Skin Substitute (ESS) at the Vatican's Third International Conference on the Progress of Regenerative Medicine and its Cultural Impact
April 25, 2016
Amarantus Announces Capital Infusion
April 21, 2016
Amarantus Announces Cancellation of Special Meeting of Shareholders
March 22, 2016
Avant Diagnostics, Amarantus Diagnostics and Theranostics Health Provide Updated Information for Conference Call to Discuss Business Combination
March 7, 2016
Avant Diagnostics and Amarantus Diagnostics to Combine Operations With Theranostics Health
March 7, 2016
Amarantus Diagnostics and Avant Diagnostics to Form 3-Way Business Combination with Theranostics Health
March 7, 2016
Amarantus Appoints Brian E. Harvey, MD PhD to Strategic Advisory Board
March 4, 2016
Amarantus Receives Notices of Allowance from European Patent Office for MANF and CDNF in the Treatment of Retinal Disorders
February 29, 2016
Amarantus and Lonza Walkersville, Inc. Provide Update on cGMP Manufacturing Readiness for the Engineered Skin Substitute (ESS) Program
February 22, 2016
Amarantus Announces $3M Capital Infusion
February 19, 2016
Amarantus Receives Orphan Drug Designation From the US FDA for Eltoprazine in the Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia
February 10, 2016
Amarantus to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
February 9, 2016
Amarantus Requests Rare Pediatric Disease Designation from US FDA for MANF in the Treatment of Retinitis Pigmentosa
February 5, 2016
Amarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS)
February 3, 2016
Amarantus Announces Issuance of Chinese Patent Covering Use of MANF for the Treatment of Parkinson's Disease
January 29, 2016
Amarantus Announces $1M Investment
January 27, 2016
Amarantus Enters Into Letter of Intent to Merge Diagnostics Business Unit Into Avant Diagnostics
January 19, 2016
Amarantus Enters into Letter of Intent to Merge Diagnostics Business Unit into Avant Diagnostics
January 19, 2016
Amarantus to Present at ICV Sonoma Event
January 15, 2016
Amarantus to Present at SeeThruEquity First Annual Microcap Healthcare Investor Conference
January 11, 2016